ABSTRACT BACKGROUND: The causes for nonadherence to mesalamine in patients with inflammatory bowel disease (IBD) have been characterized using mostly indirect methods. Patient-reported barriers are lacking in this population.
What is already known about this subject
• Patients with IBD report a number of common themes that impact their adherence.
• Doubts about efficacy, concern about side effects, and pill characteristics lead to nonadherence in these patients; these factors could be targeted by providers for intervention.
• Despite use of electronic prescribing, refills remain a barrier to adherence in these patients.
What this study adds
T he chronic nature of inflammatory bowel disease (IBD) necessitates the use of long-term medications to maintain clinical remission. As with many chronic diseases, adherence or persistence to maintenance medications is low, reportedly as low as 40% in patients with ulcerative colitis (UC) who are prescribed mesalamine. 1, 2 Low adherence has been associated with a higher risk of disease relapse, higher health care costs, and a possible greater risk of colon cancer for patients. [3] [4] [5] As a consequence, there has been an effort in recent years to identify risk factors for nonadherence in patients with IBD, and to target interventions to these factors. [6] [7] [8] Numerous analyses of payer databases and clinical practice cohorts have identified subject characteristics associated with low adherence, including gender, marital status, and pill burden. 9 However, the strength of these links is inconsistent across different studies, and many factors are not amenable to intervention by health care providers. 10 Broad, simplistic approaches to improving adherence, such as telephone reminders or education, have yielded mixed results, suggesting that adherence behavior is a more complex phenomenon. [11] [12] [13] [14] [15] Recent systematic reviews of existing intervention strategies have highlighted their limitations and the need for a further understanding of this problem. 16, 17 Our understanding of adherence behavior in patients with IBD is thus incomplete, as the methodology of many studies only allows examination of surrogate markers of beliefs or behaviors, such as gender or socioeconomic status, rather than patient-reported barriers to adherence. 2, 18, 19 Data from other diseases have identified patient-reported barriers to adherence, but these results may not be applicable to the IBD population because of the different demographic distributions of these conditions; the concerns of a woman aged 50 years with breast cancer may not mirror those of a college student aged 20 years with colitis. 20 Qualitative-based research has illustrated that enhancing medication-taking behavior in patients with IBD requires a more in-depth examination of patients' motivations. [21] [22] [23] Several patient-reported outcome measures have been developed for IBD with the goal of quantifying the holistic effects of these conditions, but they lack coverage with respect to adherence attitudes. 24, 25 The objective of this study was to understand patients' attitudes toward adherence in order to help inform a conceptual model of patients' barriers to adherence. tion was 7 years, and 13 out of 27 were also on maintenance immunomodulators or biologics because of prior moderate to severe disease. Reported adherence ranged from total adherence (n = 3) to intermittent nonadherence (n = 24). The focus groups were conducted prior to the individual interviews, and the evaluation of information saturation indicated that no new codes (themes) were added after the eighth one-on-one interview, demonstrating data saturation. A comparison of themes did not identify any differences in impacts between UC and CD patients.
From these transcripts, the barriers to adherence that patients reported were categorized under a number of themes: competing priorities, social stigma, refill inconvenience, costs, efficacy values, side effects, and pill characteristics. Sample quotations from some of these themes are presented in Table 2 .
Competing Priorities
Forgetting caused by competing tasks was the most common reason given for not taking medication as prescribed. A representative quote from one interview noted: "I'd never ever remember to take during the day because just doing all these other things and, to me, it's easier to take it at home. Once you get to work or school or whatever ... your mind is off that."
There were a variety of circumstances that interfered with remembering. These included being busy or distracted by work or other activities, or a change in routine on weekends and vacations, where the usual triggers at home that acted as
■■ Methods
This was a qualitative study in which focus groups or one-onone interviews were conducted with adults suffering from UC or Crohn's disease (CD) to identify the impact of IBD and its management, excluding surgery. Both methods were used to generate a comprehensive capture of patient-derived themes.
Qualitative Research with Patients
Participants were recruited through a tertiary clinical site specializing in the treatment of IBD. Patients were eligible if they were aged 18 years or older, had mild or moderate UC or CD in clinical remission, and were currently only prescribed mesalamine for maintenance of their IBD. All prescriptions and refills were routed via electronic prescribing for this practice. Using a standardized moderator guide, a trained interviewer asked open-ended questions to elicit patients' experiences of adherence to their IBD medications. The moderator guide and questions were developed by an IBD specialist (Moss) and qualitative researcher (Devlen) with expertise in adherence, after studying previously published examples. Both focus groups and interviews were used to ensure that no one method biased the patient-reported themes, and different patients were used for both methods. We planned 4 focus groups and 10 individual interviews a priori, consistent with general recommendations on sample size for qualitative research. Data were collected until information saturation was attained, that is, until no new information was being identified. The focus groups were convened, and interviews were conducted at the Beth Deaconess Medical Center, Boston, Massachusetts, where full institutional review board approval was obtained. All patients gave written informed consent to participate and received a small payment for their time after the interviews were completed.
Analyses
Transcripts from the focus groups and one-on-one interviews were analyzed by a single analyst following the principles of grounded theory to identify themes and possible links between themes. 26 Qualitative data analysis software MaxQDA version 10.0 (VERBI GmbH, Berlin, Germany) was used to code and facilitate organization of the data. In accordance with standard qualitative data analysis, a saturation table was constructed to assess data saturation. 27 ■■ Results A total of 27 patients (4 focus groups comprising 2-6 participants each and 10 one-on-one interviews) participated. The mean age was 31.5 years (range 20-59); 52% (n = 14) of patients were male; and 78% (n = 21) of patients had UC, while 22% (n = 6) of patients had CD (Table 1) . At the time of the interviews, 21 out of 27 patients were in clinical remission (based on Simple Colitis Clinical Activity Index < 2), but this cohort was disease-experienced. The mean disease dura- reminders were gone. Being preoccupied, particularly during the day, meant that the midday dose was often forgotten. Morning doses might be missed in the early morning rush, and in the evening, tiredness and social activities interfered with remembering the nighttime dose. The necessity for organization and advanced planning to pack medications when necessary was apparent, and many patients reported lapses in planning. Notably, some patients have developed interesting 
Efficacy Values

Time to response
Interviewer: "So, why did you switch off of the mesalamine?"
Patient #19: "I kind of gave up on it. I didn't really-I was taking these pills, and I was on it for a while. I can't even tell you how long I was on it. And, I just felt I doubted that it was even doing anything for me. So I just stopped taking it." Testing necessity of medication Patient #27: "I don't mean to insult my previous physician, but I don't think that I was-it was sort of-I wasn't given a lot of good direction in terms of how to take care of myself. So it was, you know a lot-there's no specific diet, you know? There's no magic diet, but there are things that can help, that are shown to help, and they're shown to not help overall, and I wasn't shown that. Maybe I'll just do this to help, maybe I'll take the pills every once in a while just to help it...I thought that it was just a one-time deal. If I had known that it was really possible that I could flare up again, then I would have taken it."
Pill Characteristics
Pill size Patient #12: "I can just swallow pills, any size, any quantity, and it's easy. But I would guess that for some people it would be difficult to take the large pills the way I do it. And, I've heard that people have a hard time with it. So I would say the shape and size of the medication could definitely affect some people taking their medication." Pill fatigue
Interviewer: "Are there any things that affect your ability to follow the regimen?" 
TABLE 2
Sample Quotations from Each Theme rituals to aid their adherence: "I just put them in...these little bags, these reusable bags-so, if for some reason I forget, I just fill up the bag for the whole week, so that way I know that I took it that morning. Because I get up so early...I will forget. So, every once in a while, I will try to like take it from the bottle, and then the bag will be full, and I'll be, like, did I take those? Did I not take those? So there's like a chance where there's days . . . maybe I just took 6 and maybe I took 0."
Social Stigma
Sometimes it was impractical, socially awkward, or embarrassing to take medication on time, or patients did not want others to question their physical well-being. Since a proportion of this population is frequently at college, or beginning new relationships, the stigma of disease from taking medications was commonly reported: "I guess I don't like to take it in front of people, especially people who don't know that I have ulcerative colitis and, you know, would not know why I'm taking medicine." Skipping medication on date nights, or when sleeping over with friends, emerged frequently in interviews for these reasons.
Refill Inconvenience
Hassles related to refilling prescriptions might temporarily interfere with adherence, and cost was a significant concern for a few patients. This problem often was referred to in similar terms to competing tasks; the inconvenience of having to fit a pharmacy visit into daily schedules or call physician offices for refills led to delays in obtaining refills. "I think I didn't necessarily forget, I just forgot to pick up my prescription on time, so I missed the day in between the two. But other than that, I don't forget that one either."
Costs
Cost of treatment was a significant concern for 5 patients. They reported the reduced financial burden associated with taking fewer tablets and of weighing the value of paying for treatment when they were asymptomatic. "I'd much rather pay than have to be symptomatic. But with symptoms going in remission I'd be more inclined probably to subside taking them and paying for them."
Efficacy Values
Patients who claimed not to see any benefits from their medications or were not convinced of their efficacy were less likely to adhere to their medication regimens: Why should I take it if I'm not seeing any benefits? Such patients wanted to see results for their actions. Also, some patients indicated that when they were in remission they did not feel the need to adhere as strictly to their regimens: "Why do I need to take it if I'm asymptomatic?" At least 1 patient used the term "maintenance" in an almost dismissive manner, suggesting the medication was perceived as a less important class of drugs: "When I start feeling better or good, then I just am under the belief that I don't have to take the medication any more. So I just stop the medication."
Side Effects
Three patients reported experiencing adverse effects that they associated with their medications, which often prompted them to discontinue one medication and switch to another.
Pill Characteristics
A few patients made remarks about the characteristics of the pills themselves, such as pill size or frequency of dosing. If they experienced adverse effects that they associated with the medication, that often prompted them to discontinue one medication and switch to another: "If they were smaller that would be great. They're kind of like horse pills. I mean, they're pretty big."
Lastly, sometimes patients just don't feel like taking their medication: "Every once in a while I'm just sick of taking it."
■■ Discussion
This qualitative research presents a comprehensive inventory of the key barriers to adherence from the perspective of the patient with chronic IBD. This is the first attempt to provide patient-level insights into the barriers to adherence in patients with IBD using focus groups and direct patient interviews. This process provides direct patient-reported factors, as has been recommended for the development of patient-reported outcomes for product development. 28, 29 Notably, this study highlights that nonadherence is driven by the interplay of multiple factors, including social stigma, competing daily priorities, efficacy beliefs, and refill inconvenience, that would require individualized interventions to address. The complexity of modern lifestyles appears to be a major barrier to multiple dosing regimens in these patients.
Our data, and other studies from patients with IBD and other chronic conditions, confirm that competing priorities in busy lifestyles are a barrier to medication adherence. 21, 30, 31 Our patient population is typically working or at college, which places medications among a long list of "things to do" on a daily basis. Our data also highlight that the impact of disruption to daily routines noted in other chronic conditions applies to the IBD population. 32 The universal use of smart phones among this patient population has led to interest in electronic mechanisms to trigger medication adherence during daily activities, with promising short-term results. 33 Other groups have used "intelligent" pill containers that remind patients if not opened. The finding in our study, however, that many patients report decanting their pills into various other storage solutions and locations may limit the utility of such devices.
Since the "value" of the maintenance medication to patients' lives drives their ranking of it among all their daily tasks, that evaluation would suggest that enhancing patient perceptions of the benefits of maintenance therapy holds promise to improve adherence. Moshkovska et al. (2008) also reported that patients' self-evaluation of the benefits of medical therapy appears to impact whether patients accept or reject their maintenance medications. 23 The impact of education or counseling to address this issue is uncertain. We previously reported that telephone counseling from trained nurses did not significantly improve objective measures of adherence, whereas others have reported that such phone calls improved patients' self-reports of adherence. 12, 14 A randomized controlled trial of educational and motivational interventions in patients with UC found that this approach maintained adherence but did not significantly improve it in baseline nonadherers. 13, 34 Further work is required to tailor motivational interventions to improve the priority of adherence in patients' lifestyles.
It is surprising in the age of electronic refills that the refill process is still perceived by patients as a burden, although this perception appears to be more prevalent among patients than providers. Preliminary data from other conditions suggest electronic refill requests from patients were one factor closely associated with > 90% medication adherence. 35 The disconnect between issued prescriptions and pharmacy refills appears to be influenced by the time between refills. 36 Finally, we found no substantial differences between UC and CD with respect to barriers to adherence, which is in line with other studies that report many more similarities than differences when comparing results by IBD diagnosis.
18,21
Limitations
The sample size of this study was small and derived from a tertiary referral center, so inherent biases may have existed in the sampled population. Data from community practice patients with IBD were lacking. This study only focused on patients who were already prescribed maintenance therapy, so it provided data on the "implementation" phase of adherence behavior, rather than the "initiation" or "discontinuation" phases. 37 ■■ Conclusions This is the first study to present a qualitative description of the barriers to mesalamine adherence for patients with IBD. The themes identified in this article provide raw material for the improvement of existing patient-reported outcomes in IBD. The results of a recent review of IBD-specific measures suggested some important areas may be missing, particularly related to therapy. 38 In addition, the themes highlighted in this study can be used to target tailored interventions to individuals with IBD to improve the complex attitudes around medication adherence.
